Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE4
20 participants
INTERVENTIONAL
2016-12-31
2017-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Rate Control in Patients With Atrial Fibrillation
NCT04513509
Atrial Fibrillation: Chronic Beta-blocker Use Versus As-needed Rate Control Guided by Implantable Cardiac Monitor
NCT05745337
Atrial Electromechanical Interval and Pulse Wave Velocity in the Prediction of Recurrence of Atrial Fibrillation
NCT00818012
RATe Control in Atrial Fibrillation
NCT00313157
Randomized Trial Comparing Diltiazem and Metoprolol For Atrial Fibrillation Rate Control
NCT02025465
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Carvedilol
carvedilol BID for 2 weeks
Carvedilol
Metoprolol tartrate
Metoprolol tartrate BID for 2 weeks
Metoprolol tartrate
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Carvedilol
Metoprolol tartrate
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Baseline ventricular rate (prior to treatment) \> 110 bpm
Exclusion Criteria
* Ejection fraction \< 35% or history of NYHA Class III/IV stage C/D heart failure
* Acute coronary syndrome, percutaneous coronary intervention, or cardiac surgery in the past 2 months
* Child-Pugh class B or C hepatic dysfunction
* Uncontrolled hypertension
* Thyroid disease
* Intolerance to beta-blockers
* History of lung disease resulting in hospitalization in the past year
19 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Creighton University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pallavi Bellamkonda, MBBS
Role: PRINCIPAL_INVESTIGATOR
Creighton University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Creighton University
Omaha, Nebraska, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
624918
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.